Qube Research & Technologies (QRT)’s NewAmsterdam Pharma NAMS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	+47,090	New	+$1.55M	﹤0.01%	2221

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NAMS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 47,090 shares worth $1.6M. The stake represents ﹤0.01% of the portfolio and ranks #2221 among its holdings.

194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Qube Research & Technologies (QRT) held 47,090 shares of NewAmsterdam Pharma worth $1.6M as of Q2 2026.
NewAmsterdam Pharma was a new Qube Research & Technologies (QRT) position in Q2 2026.
NewAmsterdam Pharma made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2221 holding.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.